Study on Combining Ipilimumab with Abiraterone Acetate and Prednisone for Patients with Advanced Prostate Cancer

Inclusion Criteria

• Must be 18 years or older and able to give informed consent.
• Have a confirmed diagnosis of prostate cancer that has spread and is resistant to hormone therapy.
• Must have low testosterone levels due to ongoing hormone therapy or surgical removal of the testicles.
• Cancer must be visible on imaging tests, such as bone scans or CT/MRI scans, and must have spread beyond the pelvic lymph nodes.
• Must show signs of cancer progression based on PSA levels or imaging tests.
• Must have a good overall health status with a performance score of 80-100 and an expected life expectancy of at least 6 months.
• Any side effects from previous treatments must have improved to a mild level or be considered stable.
• Must be able to swallow pills and follow study procedures.

Exclusion Criteria

• Have had another type of cancer within the last 5 years, except for certain skin cancers.
• Have low blood cell counts or low hemoglobin levels at the screening visit.
• Have high liver enzyme levels or bilirubin levels, unless due to Gilbert's disease.
• Have high creatinine levels, low albumin, or low potassium levels at the screening visit.
• Have significant heart disease or uncontrolled high blood pressure.
• Have had major surgery or radiation therapy within 4 weeks before starting the study.
• Have used certain hormone-blocking medications within 4 weeks before starting the study.
• Have a history of prostate cancer progression while on ketoconazole or similar treatments.
• Have allergies to any study drugs.
• Have uncontrolled medical conditions that could interfere with the study.
• Have autoimmune diseases like inflammatory bowel disease or lupus.
• Have known or suspected brain cancer spread or untreated brain lining disease.
• Have active infections or medical conditions that make prednisone use unsafe.
• Have active or symptomatic viral hepatitis or chronic liver disease.